February
Sunday 7 January 2018 photo 1/15
|
Cpic guidelines phenytoin: >> http://vmo.cloudz.pw/download?file=cpic+guidelines+phenytoin << (Download)
Cpic guidelines phenytoin: >> http://vmo.cloudz.pw/read?file=cpic+guidelines+phenytoin << (Read Online)
dutch pharmacogenetics working group
cpic guidelines warfarin
pharmgkb
dpwg
6 Aug 2014 Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Caudle KE(1), Rettie AE(2), Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are periodically updated at www.pharmgkb.org. PMCID: PMC4206662.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing. Article · August 2014 with 45 Reads. DOI: 10.1038/clpt.2014.159 · Source: PubMed. Cite this publication. Kelly E Caudle at St. Jude Children's Research Hospital · Kelly E Caudle. 33.56; St.
5 Aug 2014 Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Additionally, patients with the CYP2C9
Rx Annotations. Dosing GuidelineAnnotation of CPIC Guideline for phenytoin and CYP2C9,HLA-B. Please note that alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complimented in PharmGKB annotations.
20 Jan 2017
20 Jan 2017
5 Sep 2014 Guidelines regarding the use of pharmacogenomic tests for CYP2C9 and HLA-B in dosing phenytoin have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Phenytoin is broadly used to treat epilepsy, but it has a narrow
26 Sep 2017 Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (November 2014). Tables and figures included in the supplementa or referenced in the guideline:
The drug?specific evidence linking HLA?B*15:02 and SJS/TEN is discussed in the CPIC guideline for HLA?B genotype and carbamazepine dosing 4 and may have implications for choosing alternatives to phenytoin in those who carry the HLA?B*15:02 allele.
Cite As: Caudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S. E., Lee, M. T. M., Callaghan, J. T. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing. Clinical Pharmacology and Therapeutics, 96(5), 542–548.
Annons
Visa toppen
Show footer